Media ReleasesAirXpanders Inc

View All AirXpanders Inc News


AirXpanders Announces 5th Prospective Trial Confirms Physician and Patient Satisfaction, Ease of Use and Convenience with AeroForm® Tissue Expander System

- Data on delivery of radiation with AeroForm in vivo with no increased toxicity also presented

PALO ALTO, CA, United States, October 9, 2017 — AirXpanders, Inc. (ASX:AXP) (AirXpanders or Company), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today announced that new data on the use of its AeroForm® Tissue Expander System was presented during the 86th Plastic Surgery: The Meeting, the annual scientific meeting of the American Society of Plastic Surgery (ASPS), October 6-10, in Orlando, FL.


For further information please download PDF attached:
Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.